Abstract
The incidence of brain metastases exceeds 100,000 per year in the United States (21), thus making tumor metastasis to the central nervous system (CNS) a significant challenge in the management of patients with solid tumors. To put this into perspective, brain metastases occur at almost one order of magnitude greater than primary malignant brain tumors. Metastatic tumors to the brain and spine also arise in approx 10 to 15% of patients with systemic cancers. This incidence rises to approx 24% when results from autopsy studies are factored in. Patients with intracranial and intraspinal metastases comprise approx 5% of all cancer patients (4). Despite this preponderance of metastatic tumors to the CNS vs primary malignancies of the nervous system, the amount of research effort directed at the two sources of CNS disease is disparate. This is evidenced by the low number of scientific publications, a little more than 300 on brain metastases published between 1998 and 2000. However, during the same period more than 5000 publications were devoted to primary brain neoplasms. This disparity in attention to metastatic tumors of the CNS may be explained, at least in part, by the clinical complexity inherent in treating metastatic cancer. The diversity of the tumor histologies that metastasize to the brain and spinal cord combined with the absence of good clinical studies of the effectiveness of various forms of therapies, e.g., systemic chemotherapy vs radiation therapy, has hampered progress in developing efficacious therapies. Most clinical trials that have attempted to study the value of systemic chemotherapy for this group of patients have included “all comers” representing patients with multiple histologies. Metastatic tumors to the CNS arise most frequently in patients who have primary lung cancer (35–50%), particularly in patients who have small cell lung cancer (SCLC) (18). Metastases from solid tumors of the breast account for approx 10–30% of metastatic disease, followed by malignant melanoma with a 30–40% frequency of occurrence, and approx 5% for renal and colorectal cancer. The remaining other metastases to the brain (15%) are from systemic neoplasms, including nonsolid tumors, such as leukemia and lymphoma. By the time these diseases are discovered, they have frequently resulted in multiple brain metastases. In contrast to malignant melanoma, lung and breast carcinomas, which frequently have multiple brain metasta-ses, patients who have colorectal and renal cell carcinoma typically have a single brain metastasis at the time of diagnosis (10,34). The challenge of treating patients with tumors metastatic to the CNS is compounded by the fact that these space-occupying lesions are within the closed, confined cranial vault. Patients typically demonstrate a slow decline in their physical, cognitive, and emotional functions as a consequence of the growing metastatic foci. Other patients, however, may have a focus of disease in a relatively silent area of the brain. Few symptoms are obvious in these patients until the brain is overwhelmed and a sudden decompensation and a decreased level of consciousness ensues. Typically, patients with metastatic tumors to the CNS have symptoms that include headache, change in mental status, somnolence, cranial nerve palsies, dysphasia, visual field defects, hemiparesis, and focal or generalized seizures (34). Because many patients with systemic cancers are living longer, there is an increased likelihood that metastatic disease will occur in the CNS. Furthermore, the incidence of cancers such as malignant melanoma and lung cancer is increasing. The successful management of late-stage metastatic disease has thus become a clinical imperative. Although surgical resection of symptomatic lesions and whole-brain cranial radiotherapy have improved survival, more effective treatments for metastatic disease will ultimately reside in as yet undiscovered treatment strategies (53). These will undoubtedly include innovative, novel chemotherapy regimens.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adams F., Quesada J.R., Gutterman J.U. 1984. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 252:938–941.
Agoola O., Benoit B., Cross P., et al. 1998. Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int. J. Radiat. Oncol. Biol. Phys. 42:155–159.
Balis F.M., Poplack D.G. 1989. Central nervous system pharmacology of antileukemic drugs. Am. J. Pediatr. Hematol. Oncol. 11:74–86.
Barron K.D., Hirano A., Araki S., Terry R.D. 1958. Experiences with neoplasm involving the spinal cord. Neurology 9:91–106.
Bigler R.E., Zanzonico P.B., Cosma M., Sgouros G. 1988. Adjuvant radioimmunotherapy for micrometastases: a strategy for cancer cure, inRadiolabeled Monoclonal Antibodies for Imaging and Therapy, (Srivastava S.C., ed.), Plenum, New York, pp. 409–429.
Chidel M.A., Suh J.H., Reddy C.A., et al. 2000. Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with sterotactic radiosurgery for newly diagnosed brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 47:993–999.
Curran W.J., Scott C.B., Horton J., et al. 1993. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J. Natl. Cancer Inst. 85:704–710.
Doge H., Hliscs R. 1984. Intrathecal therapy with 198Au-colloid formeningosis prophylaxis. Eur. J. Nucl. Med. 9:125–128.
Donelli, M.G., Zucchetti M., D’Incalco M. 1992. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother. Pharmacol. 30:251–260.
Fujita A., Fukuoka S., Takabatake H., Tagaki S., Sekine K. 2000. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology 59: 291–295.
Gaspar L., Scott C., Rotman M., et al. 1997. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int. J. Radiation Oncology Biol. Phys. 37:745–751.
Gaspar L.E., Scott C., Murray K., et al. 2000. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 47:1001–1006.
Gilbert M.R. 2001. Brain metastatses: still on “orphan” disease? Curr. Oncol. Rep. 3:463–466.
Grossi F., Scolaro T., Tixi L., Loprevite M., Ardizzoni A. 2001. The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer. Crit.l Rev. Oncology-Hematology 37:61–67.
Hall W.A., Djalilian H.R., Nussbaum E.S., Cho K.H. 2000. Long-term survival with metastatic cancer to the brain. Med. Oncol. 17:279–286.
Hwu W.J. 2000. New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. Oncology 14:25–28.
Kaba S.E., Kyritsis A.P., Hess K., et al. 1997. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J. Clin. Oncol. 15:1063–1070.
Kollmannsberger C., Nichol C., Bamberg M., Hartmann J.T., Schleucher N., Beyer J., et al. 2000. First-line high-dose chemotherapy +/− radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann. Oncol. 11: 553–559.
Komaki R, Cox J.D., Stark R. 1983. Frequency of brain metastasis in adenocarcinoma and large-cell carcinoma of the lung: Correlation with survival. Int. J. Rad. Oncol. Biol. Phys. 9:1467–1470.
Kovacs E.J., Beckner S.K., Longo D.L., Varesio L., Young H.A. 1989. Cytokine gene expression during the generation of human lymphokine-activated killer cells: early induction of interleukin 1 beta by interleukin 2. Cancer Res. 49:940–944.
Krisjansen, PE.G., Sorenson P.S., Hansen, M.S., et al. 1993. Prospective evaluation of the effect on initial brain metastases from small-cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating drug regimen. Ann. Oncol. 4:579–583.
Landis S.H., Murray T., Bolden S., et al. 1998. Cancer Statistics. CA Cancer J. 48:6–29
Lesser G.J. 1996. Chemotherapy of cerebral metastases from solid tumors. Neurosurgery Clin. North Am. 7:527–536.
Levin V.A. 1980. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23:682–684.
Levin V.A., Patlak C.S., Landahl H.D. 1980. Heuristic modeling of drug delivery to malignant brain tumors. Pharmacokinet. Biopharm. 8:257–296.
Levin V.A., Landahl H.D. 1985. Pharmacokinetic approaches to drug distribution in the cerebrospinal fluid based on ventricular administration in beagle dogs. J. Pharmacokinet. Biopharm. 13:387–403.
Lloyd B.H., Platt-Higgins A., Rudland P.S., Barraclough R. 1998. Human S100A4 (p9ka) induces the metastatic phenotype upon benign tumour cells. Oncogene 17:465–473.
Mashimo T., Watabe M., Hirota S., Hosobe S., Miura K., Tegtmeyer P.J., et al. 1998. The expression of the KA11 gene, a tumor metastasis suppressor, is directly activated by p53. Proc. Natl. Acad. Sci. USA 95: 11,307–11,311.
Mencel P.J., L.M. DeAngelis, R.J. Motzer. 1994. Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. Cancer 73:1892–1894.
Murray N., Livingston R.B., Shepherd F.A., James K., Zee B., Langleben A., et al. 1999. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J. Clin. Oncol. 17: 2300–2308.
Nugent, J.K., Bunn P.A., Matthews M.J., et al. 1979. CNS metastases in small cell bronchogenic carcinoma: Increasing frequency and changing pattern with lengthening survival. Cancer 44:1885–1893.
Opp M.R., Obal F.R., Krueger J.M. 1988. Effects of alpha-MSH on sleep, behavior and brain temperature: interactions with IL 1. Am. J. Physiol. 255:R914–R922.
Petersen I., Hildalgo A., Petersen S., Schluens K., Schewe C., Pacyna-Gengelbach M, et al. 2000. Chromosomal imbalances in brain metastases of solid tumors. Brain Pathol. 10:395–401.
Ponta H., Sleeman J., Herrlich P. 1994. Tumor metastasis formation, cell-surface proteins confer metastasis-promoting or suppressing properties. Biochim. Biophys. Acta. 1198:1–10.
Posner J.B., Chernik N.L. 1978. Intracranial metastases from systemic cancer. Adv. Neurol. 19:579–592.
Postmus P.E., Smit E.F. 1999. Chemotherapy for brain metastases of lung cancer: A review. Ann. Oncol. 10:753–759.
Postmus P.E., Haaxma-Reiche H., Smit E.F., Groen H.J., Karnicka H., Lewinski T., et al. 2000. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy—a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J.Clin. Oncol. 18:3400–3408.
Postmus P.E., Holthuis J.J.M., Haaxma-Reiche H., et al. 1984. Penetration of VP 16-213 into cerebrospinal fluid after high-dose administration. J. Clin. Oncol. 2:215–220.
Reddeman H., Bartelt G., Blau H-J. 1986. Intrathekale radiogoldprohylaxe un liquorbefunde bei kindern mit akuter lymphoblastischer leukose. Folia Haematol. 113:466–473.
Rigon A., Sotti G., Zanesco L., et al. Profilassi meningea con radiocolloidi nell leucemia e nel linoofa non-Hodgkin dell’infanzia. Radiol. Med. 71:517–520.
Robinet G, Thomas P., Breton P.J.L., Lena H., Gouva S., Dabouis G., et al. 2001. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer. Ann. Oncol 12:59–67.
Roetger A., Merschjann A., Dittmar T., Jackisch C., Barnekow A., Brandt B. 1998. Selection of potentially metastatic subpopulations expressing c-erB-2 from breast cancer tissue by use of an extravasation model. Am. J. Pathol. 153:1797–1806.
Rustin G.J.S., Newlands E.S., Bagshaew K.D., Begent R.H.J., Crawford S.M. 1986. Successful management of metastatic and primary germ cell tumors in the brain. Cancer 57:2108–2113.
Rustin G.J.S., Newlands E.S., Begent R.H.J., Dent J., Bagshawe K.D. 1989. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J. Clin. Oncol. 7:900–903.
Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O’Rourke M., et al. 2000. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18:2095–2103.
Smedley H., Katrak M., Sikora K., Wheeler T. 1983. Neurological effects of recombinant human interferon. Br. Med. J. 286:262–264.
Sorensen J.B., Stenbygaard L.E., Dombernowsky P., Hansen H.H. 1999. Paclitaxel, gemcitabine, and cisplatin in nonresectable non-small-cell lung cancer. Ann. Oncol. 10:1043–1049.
Stewart D.J., Lu K., Benjamin R.S., et al. 1983. Concentrations of vinblastine in human intracerebral tumor and other tissues. J. Neuro-oncol. 1:139–144.
Stewart D.J., Leavens M., Maor M., et al. 1982. Human central nervous system distribution of cis-diaminedichloro-platinum and use as radiosensitizer in malignant brain tumors. Cancer Res. 42: 2472–2479.
Sun Y., Wicha M., Leopold W.R. 1999. Regulation of metastasis-related gene expression by p53: a potential clinical implication. Mol. Carcinog. 24:25–28.
Thiebaut F., Tsuoro T., Hamada H., et al. 1987. Cellular localization of the multidrug resistance gene product in normal human tissues. Proc. Natl. Acad. Sci. USA 84:7735–7738.
Twelves C.J., Souhami R.L., Harper P.G., Ash C.M., Spiro S.G., Earl H.M., et al. 1990. The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br. J. Cancer 61:147–150.
Va der Gaast A., Sonneveld P., Mans D.R., Splinter I.A. 1992. Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data. Cancer Chemother. Pharmacol. 29:335–337.
Wheldon T.E., O’Donoghue J.A., Hilditch T.E., Barrett A. 1988. Strategies for systemic radiotherapy of micrometastases using antibody-targeted 131. I. Radiother. Oncol. 11:133–142.
Wu C.S., El-Deiry W.S. 1996. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or Bcl-2. Clin. Cancer Res. 2:623–633.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Conrad, C.A., Yung, W.K.A. (2005). Systemic Chemotherapy for Metastatic Tumors of the Central Nervous System. In: Ali-Osman, F. (eds) Brain Tumors. Contemporary Cancer Research. Humana Press. https://doi.org/10.1385/1-59259-843-9:267
Download citation
DOI: https://doi.org/10.1385/1-59259-843-9:267
Publisher Name: Humana Press
Print ISBN: 978-1-58829-042-7
Online ISBN: 978-1-59259-843-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)